biOasis Technologies Ord Shs V.BTI.H

Midatech at $1.0475

[Boomskid]

That means that V.BTI's value, as caculated by the terms of the deal, is now about 5.2¢

If U.MTP keeps that up it will be worth it to buy Bioasis instead of MTP.

Hard to imagine 6¢ these days.

jd

[prophetoffactz]

With US$20 million cash plus any cash from licensing deals and/or strategic partnerships Biodexa has enough of a cash runway to reach key hard catalysts. We need to start pricing in these catalysts over the next 18 months given the cash runway. What's a 10-15-20% chance at $12 billion given the market value of the lead clinical/near clinical programs? Additionally, what's the value of Q

[Boomskid]

pof stated, "As the CEO of Biodexa stated he defies anyone to find a greater opportunity set in biotech for a company this size!" Let's give that a thought for second. A company this size... Would a smaller one qualify? Let's take a wild guess. Bioasis !! Jingle bells, jingle bells... Bells ringing, banners flying, crowd cheering... Mr. BTI shareholder...!!! Come on

[narmac]

Hummm,,,,can anyone name a junior company which has issued over 1 Billion shares into the public markets that has actually made it in business down the road in reality??.......I can't think of one!!!,,,,maybe there are,,,,maybe!!,,,,,none of the companies I have followed or been invested in ever did,,,,,,they all failed and imploded,,,,,only the management personel involved made anything

[prophetoffactz]

"Hummm,,,,can anyone name a junior company which has issued over 1 Billion shares into the public markets that has actually made it in business down the road in reality??" If Mei Mei was asked what is the bigger threat to the advancement of xB3 the number of shares outstanding or little cash to develop the science what would she say? Saltareli also said being part of a financially

[Boomskid]

Let's get it straight. Mei Mei Tian, Saltarelli and Rathjen, because they will be joining Biodexa and receiving benefits that no shareholder can get, have no credibility when it comes to describing to shareholders how great this is.   There are many maxims in the world of marketing and promotion. One of them is to never promote the opinions of those who came from the ranks of your

[fuzzyjr]

can't deny its been brutal for the biotech sector but at the same time I believe most would agree that this really is a brutal deal for all shareholders/Bti... Question is , is someone else going to give us a better offer soon or was/is this the best offer possible given the market conditions? Does a another bid/offer/deal have to come in before the vote? What happens if it&

[prophetoffactz]

"Question is , is someone else going to give us a better offer soon or was/is this the best offer possible given the market conditions?" That's one question... No one else has stepped up yet although there is still time. That will play out. Another question, what is the upside of Biodexa given its cash runway to key catalysts over the next 18 months, etc., and its considerable

[fuzzyjr]

"Another question, what is the upside of Biodexa given its cash runway to key catalysts over the next 18 months, etc., and its considerable asset base? The dilution comes with upside. Biodexa's CEO has talked about very rare upside. Not many here care" I believe most everyone cares about all the possibilities with the many upsides you've pointed out but all also feel theyve been

[emmitfitzhume]

"By obsessively fearing dilution so much BTI has been slow-walked into catastrophic dilution."   Even POF can admit this is catastrophic.   This is an unmitigated disaster for shareholders.  JD is correct, Rathjen walks away with a sweet deal while turning her back on shareholders and leaving them with what amounts to nothing.   I would also like to know more

[KayakerBC]

POOF: "By obsessively fearing dilution so much BTI has been slow-walked into catastrophic dilution."   emmitfitzhume: Even POF can admit this is catastrophic. Sometimes, if people talk/post long enough, what they really think slips out.

[prophetoffactz]

"By obsessively fearing dilution so much BTI has been slow-walked into catastrophic dilution."   Even POF can admit this is catastrophic. -------- As I've said, a 1-in-100 year flood has wiped out Biotech City. This has been the worst biotech market in history. With much of the industry trading near or below the cash on the balance sheet catastrophic dilution shouldn't be

[Boomskid]

Ok, too funny. poof has put up an image of a flood victim. The poof victim is up to his knees in the water. Bioasis victims are underwater. The poof victim has waders on. Bioasis victims also have waders on, but the flood overflowed them. The poof victim has a lawn chair with him. He sees dry land ahead. Bioasis victims are underwater. They do not have sight of land, dry or otherwise

[G1945V]

Hello narmac. "1 Billion shares into the public markets"...a stock reverse split to follow, will fix that. Wondering what stock position we each will hold from the present, once this deal is completed. Happy New Year G1945V

[KayakerBC]

G1945V:  Wondering what stock position we each will hold from the present, once this deal is completed. My understanding:  If, for example, you have 10,000 BTI shares, upon closing, that gets converted to 9556 "Ordinary Shares" in the form of American Depositary Shares (ADS), rounded down to the nearest whole ADS.  Each ADS represents 25 Ordinary Shares.  So that

[G1945V]

"So that 9556 Ordinary Shares becomes 382.24 (round down) to 382 ADS in Biodexa Therapeutics." So what dictates the price of 1 ADS in Biodexa Therapeutics? G1945V

[KayakerBC]

So what dictates the price of 1 ADS in Biodexa Therapeutics? I think the current MTP price on the NASDAQ reflects the dilution, acquisition, and market opinion of the deal.  Those are ADS.  My expectation is the Biodexa (just Midatech renamed) will begin trading somewhere around the last MTP price and the market will take it from there.

[prophetoffactz]

If Biodexa and Ladenberg Thalmann did it right the Armistice Capital financing significantly undervalues Biodexa to virtually guarantee that the US$20 million gets on Biodexa's balance sheet. The last thing Biodexa needs is to be caught without cash before it hits key catalysts in this market. 

[G1945V]

On that basis, if one invests $5000 CAN gets 100,000 new BTI shares@ 5 cents. 100,000 BTI  converts to 382 X 10= 3820 ADS (10, 000 BTI = 382 ADS) 3820 ADSs @ let's say $1.00 Us convert to Can = $1.30. So 3820 ADS @ $1.30 CAN = $4966 CA. So the higher the Midatech stock price goes up from here to the closing of the arrangement the better. G1945V

[ronrydell]

Absolutely right...might as well ride this horse well into Q1, 2023 or later and see what happens.

[KayakerBC]

So the higher the Midatech stock price goes up from here to the closing of the arrangement the better. I doubt it will go up too much (unless BTI does too).  As the closing gets closer I would expect there to be less arbitrage opportunity.

[G1945V]

"My understanding:  If, for example, you have 10,000 BTI shares, upon closing, that gets converted to 9556 "Ordinary Shares" in the form of American Depositary Shares (ADS), rounded down to the nearest whole ADS.  Each ADS represents 25 Ordinary Shares.  So that 9556 Ordinary Shares becomes 382.24 (round down) to 382 ADS in Biodexa Therapeutics." KBC (final

[KayakerBC]

KBC (final question) Is this conversation formula fixed between now and the closing of the agreement? Or will there be a recalibration at some point? I haven't found anything in the SEC docs that says the conversion will change.  That said, there is this from Edison.  I'm not sure quite WHAT is subject to change or HOW or where they got if from. "....exchange ratio 0.9556